News Nektar eyes pivotal trials for eczema drug cast off by Lilly Nektar Therapeutics has said phase 2b results show it was right to keep faith with rezpegaldesleukin as a therapy for atopic dermatitis.
News Dupixent is first FDA-approved drug for rare skin disease The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.
News Guidance creates access gap in UK for GPP drug Spevigo People in England and Wales with severe skin disease GPP will soon be able to access a new therapy currently denied to patients in Scotland.
News Ascletis says oral acne drug shows "exceptional efficacy" Phase 3 results for Ascletis' novel acne candidate have set up filings in China and bode well for a similar drug being developed by Sagimet in the US.
News InflaRx stock halves after it drops lead drug InflaRx has abandoned its drug development programme, vilobelimab for rare skin disease pyoderma gangrenosum, cratering its share price.
News Skin Analytics' dermatology AI backed for NHS use An AI-powered tool for triaging patients with suspicious skin lesions, developed by Skin Analytics, will be used by the NHS to reduce waiting times.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face